Literature DB >> 24845028

Targeting signal transducer and activator of transcription 3 contributes to the solamargine-inhibited growth and -induced apoptosis of human lung cancer cells.

Yan Zhou1, Qing Tang, Shunyu Zhao, Fang Zhang, Liuning Li, WanYin Wu, ZhiYu Wang, Swei Hann.   

Abstract

Solamargine (SM), a major steroidal alkaloid glycoside extracted from a traditional Chinese medicinal herb, Solanum nigrum L. (SNL), has been shown to inhibit growth and induce apoptosis of various cancer cells. However, the molecular mechanisms underlying this are poorly understood. In this study, we showed that SM inhibited growth and induced apoptosis of non-small-cell lung cancer (NSCLC) cells in a time- and dose-dependent manner. To further explore this, we found that SM increased phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK) in a time-dependent fashion. SM also inhibited phosphorylation and protein expression of signal transducer and activator of transcription 3 (Stat3), a transcription factor, which was abrogated by the SB203580, a specific inhibitor of p38 MAPK. In addition, SM induced protein expression of p21, one of cyclin-dependent kinase inhibitors, and this was not observed in cell overexpression of Stat3 or cells treated with SB203580. Finally, while silencing of Stat3 had no further effect, exogenous expression of Stat3 overcame the effect of SM on cell proliferation. Collectively, our results show that SM inhibits proliferation and induces apoptosis in lung cancer cells through p38 MAPK-mediated suppression of phosphorylation and protein expression of Stat3, followed by inducing Stat3 downstream effector p21. This unveils a potential new mechanism by which SM inhibits growth of human lung cancer cells.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24845028     DOI: 10.1007/s13277-014-2047-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  29 in total

1.  P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment.

Authors:  Yi-Fan Zhao; Chong-Ren Wang; Yan-Ming Wu; Sheng-Lin Ma; Yuan Ji; Yan-Jun Lu
Journal:  Biomed Pharmacother       Date:  2011-05-05       Impact factor: 6.529

2.  Hyperosmotic stress sustains cytokine-stimulated phosphorylation of STAT3, but slows its nuclear trafficking and impairs STAT3-dependent transcription.

Authors:  Ivan H W Ng; David A Jans; Marie A Bogoyevitch
Journal:  Cell Signal       Date:  2014-01-03       Impact factor: 4.315

3.  Solamargine induces apoptosis associated with p53 transcription-dependent and transcription-independent pathways in human osteosarcoma U2OS cells.

Authors:  Xia Li; Ying Zhao; William K K Wu; Shanshan Liu; Min Cui; Hongxiang Lou
Journal:  Life Sci       Date:  2010-12-14       Impact factor: 5.037

4.  Induction of actin disruption and downregulation of P-glycoprotein expression by solamargine in multidrug-resistant K562/A02 cells.

Authors:  Xia Li; Ying Zhao; Mei Ji; Shan-Shan Liu; Min Cui; Hong-Xiang Lou
Journal:  Chin Med J (Engl)       Date:  2011-07-05       Impact factor: 2.628

5.  Action of solamargine on TNFs and cisplatin-resistant human lung cancer cells.

Authors:  Chia-Hua Liang; Li-Feng Liu; Li-Yen Shiu; Yu-Sheng Huang; Li-Ching Chang; Kou-Wha Kuo
Journal:  Biochem Biophys Res Commun       Date:  2004-09-24       Impact factor: 3.575

6.  STAT3 interacts with Skp2/p27/p21 pathway to regulate the motility and invasion of gastric cancer cells.

Authors:  Zheng Wei; Xian Jiang; Haiquan Qiao; Bo Zhai; Lianfeng Zhang; Qiang Zhang; Yuanhong Wu; Hongchi Jiang; Xueying Sun
Journal:  Cell Signal       Date:  2013-01-17       Impact factor: 4.315

7.  Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3: Targeting survival pathways to increase PDT efficacy in ovarian and lung cancer.

Authors:  Christine Edmonds; Sarah Hagan; Shannon M Gallagher-Colombo; Theresa M Busch; Keith A Cengel
Journal:  Cancer Biol Ther       Date:  2012-09-17       Impact factor: 4.742

Review 8.  Targeted therapies for non-small cell lung cancer.

Authors:  Wolfram C M Dempke; Tamas Suto; Martin Reck
Journal:  Lung Cancer       Date:  2009-11-14       Impact factor: 5.705

9.  A novel compound RY10-4 induces apoptosis and inhibits invasion via inhibiting STAT3 through ERK-, p38-dependent pathways in human lung adenocarcinoma A549 cells.

Authors:  Pingping Xue; Yang Zhao; Yang Liu; Qianying Yuan; Chaomei Xiong; Jinlan Ruan
Journal:  Chem Biol Interact       Date:  2013-12-01       Impact factor: 5.192

10.  STAT3 upregulates miR-92a to inhibit RECK expression and to promote invasiveness of lung cancer cells.

Authors:  H-Y Lin; C-H Chiang; W-C Hung
Journal:  Br J Cancer       Date:  2013-07-02       Impact factor: 7.640

View more
  10 in total

1.  Maintaining a regular physical activity aggravates intramuscular tumor growth in an orthotopic liposarcoma model.

Authors:  Mohamad Assi; Frédéric Derbré; Luz Lefeuvre-Orfila; Dany Saligaut; Nathalie Stock; Mickael Ropars; Amélie Rébillard
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

2.  Inactivation of PI3-K/Akt and reduction of SP1 and p65 expression increase the effect of solamargine on suppressing EP4 expression in human lung cancer cells.

Authors:  YuQing Chen; Qing Tang; JingJing Wu; Fang Zheng; LiJun Yang; Swei Sunny Hann
Journal:  J Exp Clin Cancer Res       Date:  2015-12-21

3.  Activation of AMPKα mediates additive effects of solamargine and metformin on suppressing MUC1 expression in castration-resistant prostate cancer cells.

Authors:  SongTao Xiang; QiuHong Zhang; Qing Tang; Fang Zheng; JingJing Wu; LiJun Yang; Swei Sunny Hann
Journal:  Sci Rep       Date:  2016-11-10       Impact factor: 4.379

4.  Interplay of DNA methyltransferase 1 and EZH2 through inactivation of Stat3 contributes to β-elemene-inhibited growth of nasopharyngeal carcinoma cells.

Authors:  JingJing Wu; Qing Tang; LiJuan Yang; YuQing Chen; Fang Zheng; Swei Sunny Hann
Journal:  Sci Rep       Date:  2017-03-30       Impact factor: 4.379

5.  OSU-A9 inhibits pancreatic cancer cell lines by modulating p38-JAK-STAT3 signaling.

Authors:  Wan-Chi Tsai; Li-Yuan Bai; Yi-Jin Chen; Po-Chen Chu; Ya-Wen Hsu; Aaron M Sargeant; Jing-Ru Weng
Journal:  Oncotarget       Date:  2017-04-25

6.  Solamargine inhibits gastric cancer progression by regulating the expression of lncNEAT1_2 via the MAPK signaling pathway.

Authors:  Runjia Fu; Xiaohong Wang; Ying Hu; Hong Du; Bin Dong; Sheng Ao; Li Zhang; Zhijian Sun; Lianhai Zhang; Guoqing Lv; Jiafu Ji
Journal:  Int J Oncol       Date:  2019-03-12       Impact factor: 5.650

7.  Identification of solamargine as a cisplatin sensitizer through phenotypical screening in cisplatin-resistant NSCLC organoids.

Authors:  Yi Han; Jianquan Shi; Ziwei Xu; Yushan Zhang; Xiaoqing Cao; Jianhua Yu; Jie Li; Shaofa Xu
Journal:  Front Pharmacol       Date:  2022-08-10       Impact factor: 5.988

8.  Targeting EP4 downstream c-Jun through ERK1/2-mediated reduction of DNMT1 reveals novel mechanism of solamargine-inhibited growth of lung cancer cells.

Authors:  Yuqing Chen; Qing Tang; Qian Xiao; LiJun Yang; Swei S Hann
Journal:  J Cell Mol Med       Date:  2016-09-13       Impact factor: 5.310

9.  The regulation and interaction of colon cancer-associated transcript-1 and miR7-5p contribute to the inhibition of SP1 expression by solamargine in human nasopharyngeal carcinoma cells.

Authors:  JingJing Wu; XiaoJuan Tang; ChangJu Ma; Yao Shi; WanYin Wu; Swei Sunny Hann
Journal:  Phytother Res       Date:  2019-12-10       Impact factor: 5.878

10.  Solamargine inhibits proliferation and promotes apoptosis of CM-319 human chordoma cells through suppression of notch pathway.

Authors:  Junqi Liu; Zhenlin Wang; Cong Xu; Yan Qi; Qiuhang Zhang
Journal:  Transl Cancer Res       Date:  2019-04       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.